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BACKGROUND: Telomeres, located at chromosome ends, are progressively shortened during each cell cycle by replication-dependent
loss of DNA termini. Although maintenance of telomere length is critical for cell-replicative potential and tumourigenesis, the erosion
of telomeres can lead to genetic instability, a pivotal mechanism in the neoplastic process.
PATIENTS AND METHODS: A total of 118 colorectal cancer (CRC) samples (53 right-colon, 30 left-colon, and 35 rectal tumours) and
corresponding adjacent non-cancerous tissues were evaluated for telomere length, p53 mutation, and microsatellite instability (MSI).
Telomere length was estimated by real-time PCR.
RESULTS: Telomeres were significantly shorter in CRCs than in adjacent tissues, regardless of tumour stage and grade, site, or genetic
alterations (Po0.0001). Moreover, in normal tissues, but not in tumours, telomere length inversely correlated with age (r¼ 0.24,
P¼0.017). Telomere length in CRCs did not differ with tumour progression or p53 status; however, in CRCs carrying the wild-type
p53, telomeres were significantly shorter in tumours with MSI than in those with stable microsatellites (P¼0.027). Furthermore,
telomere length differed according to tumour location, being longer in rectal cancers (P¼0.03).
CONCLUSIONS: These findings suggest that telomere shortening is a key initial event in colorectal carcinogenesis. The extent of
telomere erosion is related to tumour origin site and may be influenced by the mismatch repair pathway.
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Colorectal cancers (CRCs) encompass a heterogeneous complex of
diseases differing in molecular pathways and biological charac-
teristics, arising through a multistep carcinogenic process, of
which several genetic and epigenetic events have been charac-
terised. There are at least two major pathways by which molecular
events can lead to CRC: loss of heterozygosity with chromosomal
instability, and a deficient DNA mismatch repair pathway with
microsatellite instability (MSI) (Grady and Carethers, 2008; Ogino
and Goel, 2008; Koopman et al,2 0 0 9 ) .A l t h o u g hp53 and K-ras genes
are known to be involved in chromosomal instability-associated
carcinogenesis, MSI is frequently associated with the CpG island
methylator phenotype (Barault et al, 2008). These two pathways are
known to have a different origin and clinical outcome; right-sided
proximal colon tumours are often MSI-associated lesions and have
a better prognosis than left-sided distal tumours (Iacopetta, 2002;
Gervaz et al, 2004; Walther et al, 2008). Rectal tumours are thought
to arise through mechanisms similar to left-colon cancers; recently,
it has been proposed that they constitute a third entity displaying
specific characteristics (Li and Lai, 2009).
Telomere dysfunction has emerged as having a causative role in
carcinogenesis by promoting genetic instability. Indeed, telomeres
are specialised DNA structures located at the end of chromosomes;
they are composed of (TTAGGG)n tandem repeats and are
essential for stabilising chromosomes by protecting them from
end-to-end fusion and DNA degradation. Telomeres are progres-
sively shortened during each cell-replication cycle because of end-
replication problems of DNA polymerase, and telomere shortening
induces somatic cells to undergo senescence and apoptosis
(reviewed in Blackburn et al, 2006). Further erosion of telomeres
may impair their function in protecting chromosome ends,
resulting in genetic instability. Although maintenance of telomere
length by reverse transcriptase telomerase (hTERT) is critical to
preserving the replicative potential of cancer cells (Hiyama and
Hiyama, 2007; Artandi and DePinho, 2010), telomere erosion has
been proposed to have two conflicting roles: tumour suppression
and genetic instability, a key event in the initiation of carcinogenesis
(Hackett and Greider, 2002; Meeker et al, 2004; Perera et al, 2008).
The role of telomere dysfunction in colorectal carcinogenesis is
still largely undefined. Several studies demonstrated that telomeres
were shorter in CRCs than in adjacent normal mucosa (Hastie
et al, 1990; Takagi et al, 1999; Gertler et al, 2004; Garcia-Aranda
et al, 2006), but this finding was not confirmed by other studies
(Katayama et al, 1999; O’Sullivan et al, 2006). Telomeres were
also found to be significantly shorter in high-grade dysplastic
lesions (Raynaud et al, 2008) and large adenomas (O’Sullivan et al,
2006) than in normal adjacent mucosa; subsequent activation
of telomerase may explain the increase of telomere length from
preneoplastic lesions to invasive carcinoma (Raynaud et al, 2008).
However, the relationship between telomere length and tumour
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sprogression remains to be assessed. Moreover, few studies have
addressed the relationship of telomere length with the site of
tumour origin and/or molecular pathways of colorectal carcino-
genesis. The suggestion that right-colon cancers have shorter
telomeres than tumours arising in other sites (Takagi et al, 1999;
Garcia-Aranda et al, 2006) has not been confirmed in other studies
(Engelhardt et al, 1997; Gertler et al, 2004). One study suggested
that telomeres were shorter in MSI tumours than in cancers with
stable microsatellites (MSS) (Takagi et al, 2000), but a relationship
between telomere length and markers of chromosome instability in
MSS tumours has not been established yet.
Telomere length has traditionally been estimated by Southern
blotting using enzymes with restriction sites in subtelomeric DNA.
However, the large amounts of DNA required by this method limit
its use in many biological samples. Using a real-time quantitative
PCR method, we analysed telomere length in a large series of CRCs
and we then determined the association of this parameter with
tumour stage, location, and markers of genetic instability.
PATIENTS AND METHODS
Patients
For this study, 118 cases were selected from patients with a
histopathological confirmation of CRC who underwent surgical
resection at a single institution. The criteria of selection were the
availability of adjacent non-cancerous mucosa and data on p53
gene mutation and MSI status (n¼193). In all, 28 tumour samples
(14.5%) were found to have a high degree of MSI (MSI-H); this
percentage reflected that reported in literature (Kim et al, 2007;
Ogino et al, 2009) and all 28 were included in this study. In
agreement with previous reports (Kim et al, 2007; Grady and
Carethers, 2008; Ogino et al, 2009), most of the MSI-H samples
(24 of 28) had the wild-type p53 gene. An equal number of age-
matched MSS tumours were selected with the wild-type (n¼45) or
mutated (P¼45) p53 gene. The median age of selected patients was
65 years (range 41–82 years); 49 were women and 69 were men.
According to the American Joint Committee on Cancer staging
(Greene et al, 2002), 23 tumours were classified as stage I (T1–T2,
N0, M0), 37 as stage II (T3–T4, N0, M0), 29 as stage III (any T,
N1–N2, M0), and 29 as stage IV (any T, any N, M1). Moreover,
18 tumours were classified as grade 1, 78 as grade 2, 17 as grade 3,
and 5 were mucinous. Grading was assessed independently by two
pathologists. Tumours were located in the right colon in 53 cases
(44.9%), in the left colon in 30 cases (25.4%), and in the rectum in
35 cases (29.7%). At the time of sampling, each patient signed the
informed consent form approving the use of his or her biological
samples for research purposes. The study was approved by the
local ethical committee.
Samples
Tissues specimens were obtained at the time of surgery,
immediately shock frozen in liquid nitrogen, and stored at
 801C until use. Cryostat sections of 6mm thickness from each
tissue sample were prepared using a 1720 Digital cryostat (Leitz,
Germany). One section of each sample was stained with
haematoxylin–eosin for histopathology. All tumour samples
analysed for telomere length contained 480% tumour cells.
DNA was extracted by the standard phenol/chloroform method
from frozen tissues.
Telomere length measurement by quantitative real-time PCR
Telomere length was determined using real-time PCR (Cawthon,
2002; O’Callaghan et al, 2008) with minor modifications.
Two PCRs were performed for each sample, one to determine
the cycle threshold (Ct) value for telomere (T) amplification and
the other to determine the Ct value for the amplification of a
single-copy (S) control gene (acidic ribosomal protein P0, RPLP0).
The primer sequences for telomere amplification were TEL1B
50-CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT-30
and TEL2B 50-GGCTTGCCTTACCCTTACCCTTACCCTTACCCT
TACCCT-30 (O’Callaghan et al, 2008) and those for RPLP0
amplification were RPLP01 50-CAGCAAGTGGGAAGGTGTAA
TCC-30 and RPLP02 50-CCCATTCTATCATCAACGGGTACAA-30
(Boulay et al, 1999). Each PCR reaction was performed using a
10ml sample (1ng of DNA per ml) and a 40ml mixture containing
1.25U AmpliTaq Gold DNA polymerase (Applied Biosystems,
Foster City, CA, USA), 150nM 6-ROX, 0.2  SYBRGreen I nucleic
acid stain 10000  (Invitrogen, Milan, Italy), 50mM KCl, 2mM
MgCl2,0 . 2 m M of each deoxynucleoside triphosphate (Applied
Biosystems), 5mM dithiothreitol, 1% dimethyl sulphoxide, and
15mM Tris–HCl pH 8.0, as well as primer pair TEL1B (300nM)
and TEL2B (900nM) or primer pair RPL01 (300nM)a n dR P L 0 2
(500nM). A reference curve was generated at each PCR run,
consisting of reference DNA from the RAJI cell line (Nishikura
et al, 1985) serially diluted from 10 to 0.41ngml
 1. All real-time
PCR reactions were carried out using the ABI Prism 7900 HT
Sequence Detection System (Applied Biosystems). Telomere and
RPLP0 sequences were amplified using the following conditions:
951C for 10min to activate the AmpliTaq Gold DNA polymerase,
and then 25 cycles each at 951Cf o r1 5sa n d5 4 1Cf o r2m i nf o r
telomere; 40 cycles each at 951Cf o r1 5sa n d5 8 1Cf o r1m i nf o r
RPLP0. ABI Prism software version 2.3 was used for analysis.
Intra- and inter-assay reproducibility of both telomere and RPL0
PCR results was evaluated initially in a series of experiments
using dilutions of the reference curve. The s.d. of Ct values was
p0.189 (% coefficient of variation p1.13) in six replicates
of samples amplified in the same PCR run, and p0.251
(% coefficient of variation p1.58) among mean values of
triplicates in different PCR runs. Both reference and sample DNAs
were analysed in duplicate. Variation of Ct values in the sample
was p0.3 Ct (s.d. p0.212; % coefficient of variation p1.25) in
both telomere and RPL0 PCR runs. Mean Ct values were used to
calculate the relative telomere length using the telomere/single-
copy-gene ratio (T/S) according to the formula: DCtsample¼
Cttelomere Ctcontrol, DDCt¼DCtsample DCtreference curve (where
DCtreference curve¼Cttelomere Ctcontrol ) and then T/S¼2
 DDCt
(Cawthon 2002; O’Callaghan et al, 2008).
Telomere length measurement by Southern blotting
In an initial series of samples, telomere length was also determined
by Southern blotting. Aliquots of 5mg DNA were digested with Hinf1
and Rsa1 restriction enzymes (20U each) for 3h at 371C. Digested
telomere restriction fragments were separated by 0.8% agarose gel
electrophoresis. Gels were transferred to a positively charged nylon
membrane and were UV cross-linked for 5min. Hybridisation was
performed with the TeloTAGG telomere length assay kit (Roche
Diagnostics, Mannheim, Germany) according to the manufacturer’s
recommendations. Briefly, filters were hybridised with a digoxigenin
(DIG)-labelled telomere-specific probe for 3h at 421C, washed twice,
and then incubated with a DIG-specific antibody coupled to alkaline
phosphatase (AP) for 30min. Hybridisation was finally visualised
using AP-metabolising CDP-Star (Disodium 2-chloro-5-(4-methoxy-
spiro {1,2-dioxetane-3,2’-(5’-chloro)tricyclo-[3.3.1.13,7]decan}-4-yl)-
1-phenyl phosphate; Sigma, St Louis, MO, USA), a highly sensitive
chemiluminescent substrate. Membranes were scanned and telomere
lengths were estimated by densitomer analysis (Gel Doc 100, Biorad,
Milan, Italy).
Quantification of hTERT transcripts
Extraction of RNA from CRC samples and reverse transcription of
RNA into cDNA were carried out as previously described (Terrin
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in CRC samples was carried out by real-time PCR, exactly as
previously described (Terrin et al, 2007, 2008), and normalised for
10
3 copies of the housekeeping hypoxanthine guanine phosphori-
bosyl transferase 1 (HPRT1) gene (Terrin et al, 2008).
P53 and MSI analyses
P53 gene mutations were detected by PCR single-strand confor-
mational polymorphism (SSCP) analysis of exons 4–8, and DNA
sequencing of samples with abnormal SSCP results (Bertorelle
et al, 1995). The MSI status was determined by analysing
five microsatellites of the Bethesda recommended panel (BAT-25,
BAT-26, D2S123, D5S346, and D17S250) (Pucciarelli et al, 2003),
and defining high MSI (MSI-H) tumours as those with two or more
altered markers (Boland et al, 1998).
Statistical analysis
Comparisons of telomere length in normal and neoplastic tissues
according to gender, site of disease, tumour stage and grade,
MSI and p53 status were performed using the Kruskal–Wallis test.
The relationship between telomere length and age was explored
with the Spearman’s rank correlation coefficient. The diagnostic
performance of T/S values was evaluated using a receiver-
operating characteristic curve; the cutoff point corresponding to
the maximum Younden index was selected to better discriminate
between normal and cancerous tissue. Results were reported with
their 95% confidence intervals (CI). Multiple linear regression
analyses were used to determine the adjusted association of
telomere length with tumour location, age, p53 and MSI status.
All P-values were two-sided, and P-value of o0.05 was considered
statistically significant. Statistical analyses were performed using SAS
stastical software (SAS Institute, Cary, NC, USA).
RESULTS
Telomere length in cancer tissues and adjacent
non-cancerous mucosa
In 118 tumour samples and the corresponding adjacent non-
cancerous tissues, telomere length was determined by real-time
PCR. For 42 cases, telomere length was also assessed by Southern
blotting. A significant linear correlation was found between the
T/S values provided by real-time PCR and the telomere length
estimated by Southern blot (rs¼0.860, 95% CI 0.77–0.92,
Po0.0001, Figure 1). Overall, the median level of T/S values in
cancer samples was 0.64 (interquartile range (IQR), 0.47–0.99),
lower than that estimated in adjacent mucosa (median 1.84
(1.47–2.63); Po0.0001) (Figure 2A). Conversion of T/S values in
Kb, using the relationship shown in Figure 1, indicated that
telomere length varied from 3.38 to 7.44Kb with a median (IQR)
of 4.10 (3.83–4.64)Kb in tumours, and from 3.61 to 11.55Kb
with a median of 5.93(5.36–7.15)Kb in normal tissues.
Telomere lengths were shorter in cancers than in adjacent
non-cancerous mucosa for all tumour stages (Po0.0001; Figure 2B)
and grades (median (IQR) 0.63(0.47–0.97) vs 2.04(1.40–2.41),
0.67(0.46–1.02) vs 1.87(1.49–2.78), and 0.59(0.45–0.78) vs
1.68(1.45–2.21) for grades 1, 2, and 3, respectively; tumours
vs normal tissues Po0.0001). Although no correlation was found
between age and telomere length in cancers, telomere length
in normal tissues inversely correlated with age (r¼ 0.24, 95% CI
 0.42  0.05, P¼0.017; Figure 2C). A patient-by-patient compa-
rison of matched tissue samples showed that all but four cases had
longer telomeres in non-cancerous mucosa than in CRC samples
with a median difference of 1.22 (0.61–1.81); these differences
inversely correlated with age (r¼ 0.23, 95% CI  0.41–0.04,
P¼0.023). From the receiver-operating characteristic curve
analysis, the T/S value that best discriminated between the
telomere length of neoplastic and normal tissues was 1.14. By
using this cutoff value, sensitivity and specificity of the assay
for cancer-associated telomere were 83% (95% CI 75–90%) and
92% (95% CI 85–96%), respectively (Figure 2D).
Relationship between telomere length and tumour
characteristics
Telomere lengths did not significantly differ with tumour stage.
Median (IQR) T/S values were 0.66 (0.56–0.66), 0.69(0.49–0.93),
0.55(0.39–1.02), and 0.64 (0.51–0.98) in tumour stages I, II, III, and
IV, respectively (Figure 2B, overall, P¼0.472). A similar observa-
tion was found by comparing T/S values with tumour grade;
T/S values did not differ between well-differentiated (median 0.63,
IQR 0.47–0.97), moderately differentiated (0.67, 0.46–1.02), and
poorly differentiated tumours (0.59, 0.45–0.78) (overall, P¼0.561).
The CRCs were then stratified according to p53 and MSI status:
an equal number of MSS tumours had the wild-type (n¼45) or
mutated (n¼45) p53 gene; 24 MSI-H tumours had the wild-type
p53 gene, whereas four tumours showed the rare pattern of both
MSI-H and the mutated p53 gene. Median (IQR) T/S values were
0.65(0.50–0.98) and 0.62(0.43–0.97) in CRCs with the wild-type
(n¼69) and mutated p53 gene (n¼49), respectively, and
0.66(0.46–1.03) and 0.56(0.43–0.73) in MSS (n¼90) and MSI-H
tumours (n¼28), respectively (P¼0.065) (Figures 3A and B).
Furthermore, in tumours carrying the wild-type p53 gene,
telomeres were significantly shorter in MSI-H (n¼24) than
in MSS cases (n¼45) (0.56(0.43–0.73) vs 0.70(0.50–1.113),
P¼0.027) (Figure 3C). In MSS tumours, those carrying the
mutated p53 gene had shorter telomeres than those carrying
the wild-type p53 gene, but this difference was not statistically
significant (0.62(0.43–0.97) vs 0.70(0.50–1.113), P¼0.218) (Figure 3C).
Telomere lengths also differed according to tumour location.
Median (IQR) T/S values were 0.57 (0.41–0.82), 0.61(0.44–0.98),
and 0.78(0.62–1.09) in the 53 right-colon, 30 left-colon, and
35 rectal carcinomas, respectively (overall, P¼0.03; right colon vs
rectum P¼0.009) (Figure 4). Normal tissues surrounding colon
and rectal tumours did not significantly differ (median (IQR) 1.82
(1.48–2.51), 2.13(1.49–2.86), and 1.87(1.25–2.61) in right-colon,
left-colon, and rectal tissues, respectively; P¼0.81). It can be noted
that 49% (26 of 53) of right-colon tumours but only 3% (2 of 65) of
left-colon and rectal cancers showed MSI. The four cases with both
MSI and the p53-mutated gene were also right-colon cancers.
rs = 0.860
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T
e
l
o
m
e
r
e
 
l
e
n
g
t
h
 
(
k
b
)
12
10
8
6
4
2
0
Relative telomere length (T/S value)
012345
Figure 1 Correlation between telomere lengths estimated by Southern
blotting (Kb) and real-time PCR (T/S value). A significant correlation
was found (r¼0.860, Po0.0001), giving the mathematical relation
y¼1.53xþ3.12.
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sIn contrast, p53 mutation occurred in a higher percentage in
left-colon and rectal tumours (60 and 43%, respectively) than in
right-colon cancers (23%). With multivariate analyses, telomere
length remained significantly associated with tumour location
after adjustment for age and p53 status (P¼0.04), as well as after
adjustment for age and p53/MSI status (P¼0.05). It is interesting
that even among MSS tumours, right-colon cancers had shorter
telomeres than left-colon and rectal cancers (median (IQR)
0.58(0.40–1.05) vs 0.62(0.44–0.98) and 0.80 (0.60–1.20), respec-
tively; P¼0.09; right-colon vs rectum P¼0.047).
Relationship between hTERT expression and tumour
characteristics
Quantification of TERT transcripts was available for 65 CRC
samples. No relationship was found between hTERT levels and
MSI status or tumour location. Indeed, median (IQR) levels of
hTERT were 82 (34–294) and 144(65–464) copies in MSI (n¼13)
and MSS CRCs (n¼52), respectively (P¼0.195), and 114(39–360),
172(71–1192), and 85(37–282) copies in right-colon (n¼22), left-
colon (26), and rectal CRCs (n¼17), respectively (P¼0.301). In
contrast, hTERT levels significantly varied with tumour progres-
sion; median (IQR) hTERT levels were 41(25–183), 82(60–161),
128(72–236), and 660(268–2543) copies in tumour stages I
(n¼20), II (n¼13), III (n¼11), and IV (n¼21), respectively
(Po0.0001), and 36(22–240), 102(70–322), and 1854(630–5739)
copies in well-differentiated (n¼14), moderately differentiated
(n¼41), and poorly differentiated tumours (n¼7), respectively
(Po0.0001). No correlation was found between telomere length
and hTERT level.
DISCUSSION
The role of telomere erosion in colorectal carcinogenesis is
still largely undefined. Using a real-time PCR assay, which
requires a considerably low quantity of biological samples, we
estimated telomere length in a large number of CRCs and in
corresponding adjacent non-cancerous mucosa. For the first time,
we determined the relationship between telomere length and
tumour progression and location, as well as its relationship to
MSI and p53 mutation status, two markers of major pathways
of genetic instability in CRCs. Overall, our results indicated that
(i) telomeres in CRCs were consistently shorter than those of
adjacent non-cancerous mucosa, regardless of tumour stage and
grade, site, or genetic alterations; (ii) telomeres were shorter in
MSI than in MSS carcinomas, and the difference was significant
between MSI and MSS tumours carrying the wild-type p53 gene;
(iii) regardless of genetic alterations, telomeres were shorter in
tumours arising from the right colon and were longer in rectal
cancers.
In agreement with previous studies (Hastie et al, 1990; Gertler
et al, 2004), we found that telomere length decreased with ageing
in normal mucosa, but not in tumours. It has been proposed that
telomere shortening with age may increase the risk of cancer
(Blasco, 2005; Risques et al, 2008); this concept may be supported
by our results, as telomere shortening between normal and
neoplastic tissues was found to be inversely correlated with age.
Although telomere length in somatic cells primarily reflects
cellular proliferation, telomere length in tumour cells reflects the
balance between cellular proliferation with telomere loss and
telomerase activity with de novo synthesis of telomeric sequences.
Evidence that telomeres were shorter in CRCs than in adjacent
mucosa, even in well-differentiated tumours, strongly supports
the concept that telomere erosion is a critical initial event in
colorectal carcinogenesis. It is likely that stabilisation and
maintenance of telomeres, essential to preventing cellular sene-
scence and conferring unlimited replicative potential, occur after
initial extensive cellular proliferation. It is noteworthy that,
although several studies agree that there is a shortening of
telomeres in preneoplastic lesions (O’Sullivan et al, 2006; Raynaud
et al, 2008), the relationship between telomere length and tumour
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sprogression is still controversial (Engelhardt et al, 1997; Gertler
et al, 2004; O’Sullivan et al, 2006). We did not find any relationship
between telomere length and tumour progression. In agreement
with previous studies (Terrin et al, 2008), levels of hTERT increased
with tumour progression; it is conceivable that telomere length
may stabilise with tumour progression because of an increase in
telomerase activity compensating for replicative telomere loss.
It should be pointed out that B15% of CRCs presented MSI-H,
whereas the p53 gene is the known major genetic alteration in CRCs
with MSS (Kim et al, 2007; Ogino et al, 2009). A link between
telomere shortening and MSI-H has been suggested in a previous
study of 55 CRCs; all MSI tumours (n¼8 )b u to n l yh a l fo ft h e
remaining MSS tumours had shorter telomeres than those found in
adjacent normal mucosa (Takagi et al, 2000). Our study conducted in
a larger number of CRCs demonstrated that both MSI-H and MSS
tumours had shorter telomeres than those found in adjacent mucosa
and that MSI-H had shorter telomeres than MSS cancers. The MSI
pathway involves a failure of the mismatch repair system (Aaltonen
et al, 1993), which maintains genetic stability not only by repairing
DNA replication errors but also by preventing chromosomal
recombinations; a deficiency of mismatch repair helps cells over-
come cellular crises caused by critical shortening of telomeres
(Bechter et al, 2004). Thus, MSI cells may undergo more proliferative
cycles and a more pronounced shortening of telomeres before
stabilising than MSS cells. It is of interest that the difference was
particularly high and significant when MSI tumours were compared
with MSS tumours carrying the wild-type p53 gene. It can be noted
that MSS tumours with the mutated p53 gene had slightly shorter
telomeres than MSS tumours with the wild-type p53 gene. In cells
with mutated p53, telomeres may protract their shortening along
with cell proliferation, However, p53 is a well-known negative
regulator of hTERT promoter, and mutated p53 may also result in
hTERT activation (Liu et al, 2004); thus, stabilisation of telomeres
may occur earlier than in MSI tumours.
We found that right-colon tumours displayed significantly shorter
telomeres than tumours arising from other sites. In agreement with
previous studies (Iacopetta, 2002; Gervaz et al, 2004; Walther et al,
2008), we found that MSI status was strongly associated with tumour
origin in the right colon. However, this association could only
partially explain the finding that telomeres were shorter in right-
colon cancers, as half of these tumours were MSS. Interestingly, even
in MSS tumours, those arising in the right colon had significantly
shorter telomeres than those arising in the rectum. The prognosis of
rectal cancers is worse than that of colon cancer and it is currently
under debate whether rectal cancers are actually a distinct entity.
Telomere length distinguishes colon from rectal cancers; as telomere
lengths of normal tissues surrounding colon and rectal cancers did
not differ, it is likely that the different telomere length in cancers is
due to a different kinetics of telomere erosion/stabilisation in colon
and rectal carcinogenesis. Although no association was found
between hTERT level and the tumour origin site, earlier activation
of hTERT may contribute to these differences between rectal and
colon cancers. Future studies on these aspects may be of help in the
design of anti-neoplastic strategies.
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Figure 3 Relative telomere lengths, expressed as T/S values, in tumours
according to (A) mutated (n¼49) or wild-type (n¼69) p53 gene, and (B)
high microsatellite instability (MSI-H) (n¼28) or stable microsatellite (MSS)
(90) status. (C) Relative telomere lengths, expressed as T/S values, in p53
mutated MSS (n¼45), p53 wild-type MSI-H (n¼24), and p53 wild-type
MSS (n¼45) tumours. Boxes and whiskers represent the 25th–75th and
10th–90th percentiles, respectively; the median is the central line in each
box.
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90th percentiles, respectively; the median is the central line in each box.
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